Lifeward Ltd. (LFWD) presents a deeply negative liquidation posture as of December 31, 2025. Total assets of $22.9 million face haircuts that substantially erode recoverable value before any liabilities are addressed. Applying standard liquidation haircuts: cash and restricted cash of approximately $2.6 million recovers at par; accounts receivable of $6.1 million (net) recovers approximately $5.5-5.8 million at 90-95%; inventory of $5.7 million recovers approximately $3.4 million at 60%; PP&E net book value of $0.6 million recovers approximately $0.3-0.4 million at 50-70%; operating lease ROU asset of $1.5 million and goodwill of $4.8 million recover zero. Intangibles carried are minimal per the filing. Estimated gross liquidation asset pool: roughly $11.5-12.0 million. Against this, total liabilities at face value are $14.5 million, including current liabilities of $12.0 million (accounts payable $5.6 million, convertible notes payable current $2.8 million, deferred revenue $0.9 million, employee liabilities $1.4 million, operating lease current $0.4 million, other current $0.9 million) and non-current liabilities of $2.5 million (operating lease non-current $1.2 million, deferred revenue non-current $1.2 million, other long-term debt $0.4 million, other non-current $0.1 million). Additionally, a $6.0 million open purchase obligation and $1.9 million in future operating lease payments (undiscounted) are off-balance-sheet commitments that would need resolution. Under a strict liquidation scenario, equity recovery is materially negative, consistent with MFFAIS CLV of negative $11.0 million and LLV of negative $4.9 million. The company burned $16.8 million in operating cash in 2025 and ended the year with only $2.2 million in unrestricted cash. A $3.0 million secured promissory note issued in November 2025 to related party Oramed (15% interest, matures May 2026, secured by a lien on cash) adds a senior creditor claim directly against the most liquid asset. The $79.4 million deferred tax asset valuation allowance is 100% non-recoverable. A goodwill impairment of $2.8 million was taken in 2025, partially reducing the carrying value from the AlterG acquisition. Subsequent events include additional Oramed bridge financing totaling $1.025 million (February-March 2026) and a pending acquisition of Oratech Pharma, adding further contingent liability uncertainty. Filing discusses purchase obligations of $6.0 million (down from $7.5 million as of the prior Q3 filing) in MD&A but does not separately tag this in XBRL as a distinct balance sheet line; it appears only as PurchaseObligation in TAG_CONTEXT.
▼ Community Notes